作者： sarah
Honda Presents World Premiere of Honda 0 Saloon and Honda 0 SUV Prototypes at CES 2025
LAS VEGAS, NV, Jan 8, 2025 - (JCN Newswire via SeaPRwire.com) - Honda today presented the world premiere of two prototype models at CES 2025, Honda 0 Saloon and Honda 0 SUV, representing two Honda 0 Series models that will be introduced to global markets starting in 2026. Honda also introduced its original vehicle operating system (OS), the ASIMO OS, for Honda 0 Series models. Honda 0 SaloonBy further advancing the concept model introduced last year at CES 2024, the Honda 0 Saloon prototype was developed in preparation for a market launch scheduled in 2026. While maintaining the exact styling design of the concept model, the prototype model features both a low height, sporty styling that sets the Saloon apart from other EVs at first glance and an interior space that is more spacious than people can imagine based on the exterior dimensions.The Honda 0 Saloon, the flagship model of the Honda 0 Series, will be based on the newly-developed dedicated EV architecture and will feature a number of next-generation technologies that will embody the “Thin, Light, and Wise” development approach of the Honda 0 Series.At CES 2025, Honda is focusing on introducing certain technologies and features that contribute to the “Wise” value of the Honda 0 Saloon. This includes the highly reliable automated driving technologies backed by the Level 3 automated driving technology, which Honda put into practical use for the first time in the world, as well as “ultra-personal optimization” that will offer a mobility experience customized for each individual user, which will become possible with the ASIMO OS. The production model of the Honda 0 Saloon is scheduled to be introduced first in the North American market in 2026, then in global markets, including Japan and Europe. Honda 0 Series | WISE EXPERIENCE https://youtu.be/MW86NBIXIUwHonda 0 SUVBased on the Space-Hub concept model unveiled at CES 2024, proposing the new value of EVs as a “space” for people that Honda wants to offer with its future EV models, Honda presented the prototype of a mid-size EV SUV, which will be the first Honda 0 Series model. By applying the “Thin, Light, and Wise” approach to an SUV, the interior space was further increased, and a spacious cabin was achieved with an outstandingly clear and unrestricted field of view and great flexibility.As with the Honda 0 Saloon, the Honda 0 SUV will feature a wide variety of next-generation technologies which embody the “Thin, Light, and Wise” development approach of the Honda 0 Series. This model will offer the value of an “ever-advancing” space through the “ultra-personal optimization” and digital UX made possible by the ASIMO OS. Moreover, the Honda 0 SUV will apply high-precision attitude estimation and stabilization control based on 3D gyro sensors, technology Honda has amassed through the development of its original robotics technologies, to enable dynamics at the will of the driver on various types of road surfaces.The production model of the Honda 0 SUV is scheduled to be introduced first in North American market in the first half of 2026, then in global markets, including Japan and Europe.Honda 0 SUV https://youtu.be/4sIFhyG6cLcASIMO OSHonda 0 Series models will be equipped with the ASIMO OS, an original vehicle OS developed by Honda. ASIMO was a humanoid robot capable of autonomous walking, developed as part of Honda fundamental technology research with the aim of helping people while coexisting with people in society. Honda began robotics research and development in 1986, and introduced ASIMO in 2000. ASIMO became an icon in the field of robotics from the 2000s through 2010s and was loved by people all over the world for a long period of time thereafter.Honda gave the name ASIMO to this vehicle OS, the core technology to achieve the “Wise” value of the Honda 0 Series, with a determination to strive for making Honda 0 Series an icon of next-generation EVs, which will surprise and inspire people all around the world, just as ASIMO did. Even after development of ASIMO, Honda has been further advancing its robotics technologies, such as ASIMO technologies that recognize external environments and autonomous behavior control technologies that enable ASIMO to act while understanding the intentions of people around it. By combining such robotics technologies with advanced intelligence technologies for the Honda 0 Series, Honda strives to offer the value of software defined vehicles (SDVs) unique only to Honda.As a software platform, ASIMO OS will apply integrated control of electronic control units (ECUs) for vehicle systems such as automated driving/advanced driver assistance systems (AD/ADAS) and in-vehicle infotainment (IVI) system.By constantly updating the in-vehicle software based on the ASIMO OS through over the air (OTA) updates even after the purchase of the vehicle, functions and services will be continuously advanced in accordance with the preferences and needs of each individual user. The functions and services subject to constant updates include those which enhance the value of “space” and the digital UX, that ensures fun and comfortable mobility experience, and integrated control of dynamics unique to Honda, that determines the joy of driving, enabling the driver to feel at one with the vehicle.Honda is planning to install ASIMO OS to Honda 0 Series models, including production models of the Honda 0 SUV and Honda 0 Saloon.Automated driving (AD) technologyIn 2021, Honda became the world’s first automaker to put Level 3 automated driving equipment into practical use with the launch of the all-new Legend equipped with Honda SENSING Elite, which qualified for Level 3 automated driving (eyes-off), and conditional driving automation in limited areas. Honda developed Honda SENSING Elite to put this AD technology into practical use by anticipating all driving conditions and scenarios based on the premise that, in addition to reducing the number of traffic collisions in society, Honda AD must completely eliminate traffic accidents that people think a “human driver could avoid.”Honda believes that the widespread use of eyes-off technology will lead toward the realization of zero traffic collision fatalities in the future. Based on this belief, Honda will strive to offer affordable automated driving vehicles to more customers around the world through the Honda 0 Series.To this end, Honda applies an original Honda AI technology that combines the unsupervised learning*1technology of Helm.ai and the behavior models of experienced drivers, which enable AI to learn with smaller amounts of data, and efficiently expand the range of situations where automated driving and driver assistance can be available.In addition, Honda will apply its original cooperative AI developed through research into people and mobility to further improve the precision of cooperative behavior, such as yielding the right of way to others on the road, which is difficult even for a human driver. By applying these advanced technologies, Honda will realize a highly-reliable driver assistance system that can respond quickly and appropriately to unexpected situations, such as an animal darting into the lane or an object falling onto the road.Honda 0 Series models will be equipped with a system that enables the expansion of the range of driving conditions where driver assistance and Level 3 automated driving will be available. This expansion will start with eyes-off technology available in traffic congestion on highways, then will continue through the OTA updates of the functions. With Level 3 automated driving, the vehicle will be in charge of driving, which will enable a human driver to perform a “second task” while en route to their destination, whether watching a movie or remotely joining a meeting. Honda will further advance its technologies and become the first automaker to expand the application of eyes-off functions to all driving situations, opening up new possibilities for mobility.Development of SoC dedicated to Honda 0 SeriesAt the Honda press conference held at CES 2025, Honda and Renesas Electronics Corporation (Renesas) announced that they have signed an agreement to develop a high-performance system-on-chip (SoC) to realize the future SDVs Honda aims to achieve with Honda 0 Series models.For the next-generation Honda 0 Series models, which will be launched in the late 2020s, Honda will adopt a centralized E&E architecture that combines multiple ECUs, responsible for controlling vehicle systems, into a single, core ECU. The core ECU, which serves as the heart of the SDV, manages various vehicle systems, such as AD/ADAS, powertrain control, and comfort features, all on a single ECU. To achieve this, the ECU requires a SoC that provides higher processing performance than traditional systems, while minimizing any increase in power consumption.To fulfill such requirements, Honda and Renesas will realize a system that utilizes multi-die chiplet technology*2 to combine the Renesas generic fifth-generation (Gen 5) R-Car X5 SoC series with an AI accelerator optimized for AI software developed independently by Honda. With this combination, the two companies aim to develop a system that achieves one of the industry’s top class AI performances of 2,000 TOPS*3 (Sparse) with 20 TOPS/W power efficiency.Energy ServiceIn order to offer Honda 0 Series models that achieve the joy and freedom of mobility for more people with zero environmental impact, Honda will develop and offer new energy services based on two core concepts: 1) building a charging network that enables the customers to enjoy stress-free freedom of mobility and 2) enabling people to enjoy clean and smart daily lives utilizing EV batteries.As for the establishment of the charging network, Honda is striving to realize a society where 0 Series users will never have trouble recharging their vehicles. To this end, in North America, eight automakers*4 established a joint venture to create a charging network called IONNA. It aims to include at least 30,000 high-quality charging stations by 2030. In addition, by adopting the North American Charging Standard (NACS) for the charging port of Honda 0 Series models, Honda will continue making progress in expanding the charging network to ensure that Honda 0 Series owners will have access to more than 100,000 charging stations by 2030.Moreover, in line with the introduction of Honda 0 Series models, Honda is also considering a new charging service that leverages this broad charging network. By incorporating Amazon Web Services, Inc.（AWS）technologies, such as Amazon Bedrock, the generative AI technology of AWS, into Honda intelligent technology, and by analyzing data obtained from the Honda 0 Series and the extensive charging network, Honda will strive to provide a personalized charging experience for each individual in terms of finding charging facilities and simplifying payment.In order to achieve carbon neutrality, it is essential to further utilize renewable energy along with popularization of EVs. For home charging, which is expected to account for approximately 80% of all EV charging*5, Honda will further advance the Honda Smart Charge, a charging service for EV owners, which Honda is currently offering in North America, by combining the Home Energy Management System Honda is co-developing with Emporia Corp., with the Vehicle Grid Integration (VGI) system of ChargeScape, a software JV that Honda established with BMW and Ford. Through these initiatives, Honda will start offering new services that contribute to reducing electricity costs and CO2 emissions for our customers in North America and other markets starting in 2026.With this service, the collective fleet of Honda 0 Series models will also serve as a virtual power plant (VPP) and execute a personalized charging plan for each user. To be more specific, a Honda 0 Series model will charge itself by selecting times of the day when electricity costs are low and renewable energy can be utilized, and discharge the electricity for household use during times when electricity costs are high, thereby wisely managing the entire household’s electricity bill.Furthermore, when electricity is in short supply, the electricity stored in Honda 0 Series models can be supplied to the power grid, thereby contributing to the stabilization of electricity supply and enabling owners to gain some income from their EVs. Battery degradation, which can be a concern due to repeated charging and discharging, is also minimized through the use of battery management technology Honda has amassed through the development of hybrid-electric vehicles.(1) Unsupervised learning is one of the methods of machine learning, which supports AI. Unlike supervised learning through which AI learns the correct answers to derive from labeled input data, unsupervised learning lets AI learn without being provided with the correct answers and derives the patterns and unique characteristics of the unlabeled data on its own.(2) Technology to build a system by combining multiple chips (dies) with different functions(3) Tera Operations Per Second (TOPS) is a metric of AI processing performance and measures the number of operations that can be performed per second. Based on a sparse AI model.(4) American Honda Motor, a Honda subsidiary in the U.S., BMW Group, General Motors, Hyundai Motors, Kia Corporation, Mercedes-Benz Group, Stellantis N.V., Toyota Motor.(5) Honda internal researchHonda press conference at CES 2025 (livestreaming/archive)https://youtube.com/live/3M87dqNbY3U Copyright 2025 JCN Newswire via SeaPRwire.com.
Honda and Renesas Sign Agreement to Develop High-Performance SoC for Software-Defined Vehicles
TOKYO, Jan 8, 2025 - (JCN Newswire via SeaPRwire.com) - Honda Motor Co., Ltd. (TSE: 7267) and Renesas Electronics Corporation (TSE:6723) announced today that they have signed an agreement to develop a high-performance system-on-chip (SoC) for software-defined vehicles (SDVs). The new SoC is designed to deliver leading-edge*¹ AI performance of 2,000*2 TOPS combined with a world-class power efficiency of 20 TOPS/W, and is slated for use in future models of the “Honda 0 (Zero) Series,” Honda’s new electric vehicle (EV) series, specifically those that will be launched in the late 2020s. The agreement was announced during a Honda press conference held at CES 2025 in Las Vegas, Nevada on January 7.Honda is developing original SDVs to provide a mobility experience optimized for each individual customer in the Honda 0 Series. The Honda 0 Series will adopt a centralized E/E architecture that combines multiple electronic control units (ECUs) responsible for controlling vehicle functions into a single ECU. The core ECU, which serves as the heart of the SDV, manages essential vehicle functions such as Advanced Driver Assistance Systems (ADAS) and Automated Driving (AD), powertrain control, and comfort features, all on a single ECU. To achieve this, the ECU requires a SoC that provides higher processing performance than traditional systems, while minimizing any increase in power consumption.Renesas is committed to providing automotive semiconductor solutions that enable automobile OEMs to develop SDVs. Renesas’ R-Car solutions offer higher AI performance with the ability to customize by leveraging multi-die chiplet technology*3 and integrating AI accelerators*4 into its SoC.To realize the Honda vision for SDVs, Honda and Renesas reached an agreement to develop a high-performance SoC compute solution designed for core ECUs. Using TSMC’s leading-edge 3-nm automotive process technology, this SoC also can achieve a significant reduction in power consumption. Additionally, it realizes a system that utilizes multi-die chiplet technology to combine Renesas’ generic fifth-generation (Gen 5) R-Car X5 SoC series with an AI accelerator optimized for AI software developed independently by Honda. With this combination, the system aims to achieve one of the industry’s top class AI performances with power efficiency. The SoC chiplet solution will provide the AI performance required for advanced functions such as AD, while keeping power consumption low. Chiplet technology allows flexibility to create customized solutions and offers future upgrades for functional and performance improvements.Honda and Renesas have collaborated closely for many years. This agreement will accelerate the integration of advanced semiconductor and software innovations into the Honda 0 Series, enhancing the mobility experience for customers.(1) Renesas estimate as of January 2025(2) Tera Operations Per Second (TOPS) is a metric of AI processing performance and measures the number of operations that can be performed per second. Based on a sparse AI model.(3) Technology to build a system by combining multiple chips with different functions(4) Hardware designed for high-speed and high-efficiency AI (artificial intelligence) computational processing Copyright 2025 JCN Newswire via SeaPRwire.com.
Robotaxi全球商业化路径趋同 出行平台数据成必争资源
香港, 2025年1月8日 - (亚太商讯 via SeaPRwire.com) - 近日，粤港澳大湾区Robotaxi发展又有新动态。12月27日，南沙、横琴、前海、宝安共同签署了《智慧网联汽车示范应用试点互认合作框架协议》。4地将率先合作构建大湾区智慧网联汽车示范应用试点互认路径，推动智慧网联汽车示范区互联互通和开放共享。首批试点互认的合作企业包括如祺出行等4家企业，并在签约仪式上获授牌，意味着这4家企业在大湾区开展Robotaxi业务将获得更有力的政策支持和服务，可为其进一步扩大运营规模创造条件。从行业来看，11月至今中国智驾领域的公司动作频频，为即将到来的Robotaxi大规模商业化落地做着各种前置准备。小马智行先后与北汽新能源、广汽埃安就L4无人驾驶车型开发量产建立合作；百度Robotaxi获得香港批出的首张路测执照；文远知行与Uber合作计划将Robotaxi落地到阿联酋。光大证券研报称，Robotaxi作为自动驾驶商业化落地终极模式，接下来在中国将迎来高速增长阶段，预计2030年国内Robotaxi市场规模可达390亿美元，2025-2030年年复合增长率约达200%。'金三角'成Robotaxi主流发展模式业内分析认为，中国在Robotaxi商业化落地上已呈现出全球领先优势。除了政策和技术的推动因素外，在一定程度上也得益于行业在发展早期就形成'专业分工+深度合作绑定'的共识，采取'主机厂+自动驾驶公司+出行平台'的金三角模式，实现量产、技术研发和运营协同合作优势互补。据了解，早在2021年左右，国内就形成了'广汽集团-如祺出行-小马智行/文远知行'、'上汽集团-享道出行-Momenta'等多个合作阵营。而两年后的2023年10月，Uber也宣布与Waymo、捷豹合作，正式开启'金三角'合作模式，随后合作阵容不断扩大。华鑫证券认为，各国Robotaxi商业化发展路径正逐步趋同，除了特斯拉等个别企业外，更多公司转向'金三角'模式，预计合作、合资或会在Robotaxi未来一段相当长的时间内成为主流运营模式。事实上，对整个智驾产业链来说，生态合作已成为近年重要议题之一。在地平线、如祺出行、文远知行、小马智行等多家公司在IPO招股书中，均表示通过扩大产业生态合作持续推进其技术和服务商业化落地。其中，以今年7月登陆港交所的如祺出行为例，其IPO招股书显示，股东阵容包括广汽、小马智行、文远知行和滴滴自动驾驶。而其他正在IPO路上的出行平台如享道出行等，股东名单同样不乏主机厂和智驾技术公司。出行平台已成为产业链上下游积极团结的对象之一。有长期关注Robotaxi市场的分析人士认为，Robotaxi本质是出行服务，在运营环节有望诞生一到两家核心玩家，像如祺出行这样有主机厂和智驾公司双重加持、且已开始Robotaxi布局的公司或能获得先发优势。而目前，如祺出行Robotaxi服务已覆盖广州南沙、深圳宝安、南山和横琴粤澳深度合作区。数据已为智驾产业必争资源出行平台成为智驾公司积极合作的对象，背后还有一个重要推动因素 - 数据。随着端到端大模型技术应用，自动驾驶技术获得也获得突破性发展，随之进入数据驱动阶段，数据成为了驱动技术持续迭代最重要的养料。智驾公司要持续提升数据规模，比起投入大量资源扩大自有数据采集车队，与已布局Robotaxi、拥有大量运营车辆的出行平台合作，似乎是更显著的选择。以如祺出行为例，该平台在大湾区用户渗透率超过45%，且已有自动驾驶技术商业化落地场景及路测数据。2024年6月，如祺出行成为全国首批获准开展L3自动驾驶上路通行试点。不久前的广州车展上，如祺出行重点发布了基于自动驾驶运营优势和自动驾驶数据解决方案构建的数据闭环飞轮，包括如祺Robotaxi运营落地进展，以及如祺众源地图、4D标注等技术、工具及解决方案的最新成果。今年以来，受智驾技术进入端到端大模型时代、自动驾驶价值空间扩大等因素带动，AI、大模型、数据要素、Robotaxi、车路云等板块持续受到全球市场关注。关于如祺出行科技有限公司如祺出行是中国的出行服务公司，服务并连接出行行业的各类参与者，包括乘客、司机、整车制造商、车辆服务提供商及自动驾驶解决方案供应商。公司提供(i)出行服务（包括网约车、Robotaxi及顺风车服务）；(ii)技术服务，主要为AI数据及模型解决方案以及高精地图；及(iii)为司机及运力加盟商提供全套支援的车队销售及维修。公司由广汽集团和腾讯联合发起创立，其后引入一家自动驾驶解决方案供应商小马智行作为战略股东。通过连接汽车制造商、互联网公司和自动驾驶解决方案供应商，公司是推动自动驾驶技术商业化的先行者。多元化背景的股东提升了公司的市场洞察力并增进公司对整个出行服务行业价值链上主要利益相关方的了解，从而使得公司能够整合汽车和出行服务行业的资源。本新闻稿由皓天财经集团有限公司代表如祺出行科技有限公司发布详情垂询：皓天财经集团有限公司Angie Li & Jason Lai电话：(852) 6150 8598 / (852) 9798 0715电邮：projectrice@wsfg.hk Copyright 2025 亚太商讯 via SeaPRwire.com.
Mitsubishi Motors to Display Custom Versions of the Triton at Tokyo Auto Salon 2025
TOKYO, Jan 7, 2025 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Motors Corporation (hereafter, Mitsubishi Motors) will exhibit at the Tokyo Auto Salon 2025, one of the world's largest custom car shows, to be held from January 10 until January 12 at Makuhari Messe in Chiba, Japan. A total of eight vehicles will be on display, with the Triton as the centerpiece.The customized versions of the Triton one-ton pickup truck will include a vehicle customized by Hiromi, a Mitsubishi Motors brand ambassador, the winning vehicle from the Triton custom contest held in Japan, and an event vehicle equipped with a DJ booth for dance events hosted by Red Bull Japan Co., Ltd.For the plug-in hybrid electric vehicle (PHEV) model of the Outlander PHEV updated in October last year, a custom concept car inspired by the world of Metal Gear Solid series (by Konami Digital Entertainment Co., Ltd.) will be on display. There will also be a customized model of the Delica D:5 minivan, along with a Triton rally car and Delica D:5 and Delica Mini support cars from Asia Cross Country Rally 2024 (hereafter, AXCR 2024).Brand Ambassador Hiromi’s custom TritonThis customized version of the Triton was made to blend into urban driving environments by taking a pickup truck, characterized by large-diameter wheels and high ground clearance, and lowering it as close to the ground as possible. Its metal-plated parts are matte wrapped to exude a mature vibe.Winning vehicle from the Triton custom contestThe model that wins the Triton custom contest will be on display.Triton event vehicle equipped with DJ boothThis event vehicle was created through partnership with Red Bull Japan Co., Ltd. to provide a sound center for the dance events and other activities they host. The cargo bed of the Triton is equipped with a DJ booth, allowing for actual DJ performances at the events.Outlander PHEV Night Seeker ConceptBased on the Outlander PHEV with its outstanding road handling and functionality as an SUV, this custom concept car features a design inspired by the hit video game series Metal Gear Solid (by Konami Digital Entertainment Co., Ltd.). With a striking harmony between Mitsubishi Motors’ commitment to create cars that reach the destination without fail even on the harshest of roads, and the realistic stealth action of the Metal Gear Solid game series, this car is designed to captivate all generations of users who crave authenticity.Delica D:5 Black Edition Active SeekerBased on the Delica D:5 Black Edition, this car features a gunmetal matte finish with a low saturation green color. Its graphics designed to resemble the topography of Tokachi, Hokkaido, where Mitsubishi Motors’ proving ground is located, gives drivers the feeling of exploring out in the field and inspires a sense of being able to take on any type of adventure.AXCR 2024 Triton rally carThis rally car is based on the Triton, which debuted globally in 2023, and has been modified according to the Fédération Internationale de l'Automobile Group T1 specifications (modified cross-country vehicle). Reflecting on the results from the previous year's participation, its power performance has been further enhanced to compete with high-displacement rivals on high-speed stages. Additionally, the vehicle's off-road capability has been significantly improved by widening the tread and changing the rear suspension from a leaf spring system to a four-link rigid system with coil springs. This allows the Triton to maintain its good balance while also excelling in off-road speed.AXCR 2024 Delica D:5 support carLeveraging the Delica D:5’s robustness, maneuverability and road handling, this support car is equipped with a lift-up suspension, off-road tires, and an aluminum engine guard to improve its off-road capabilities. During AXCR 2024, it successfully supported Team Mitsubishi Ralliart by comfortably and reliably navigating a tough course of over 2,000 km across seven days.AXCR 2024 Delica Mini support carDebuting in the AXCR 2024, the Delica Mini support car is equipped with a lift-up suspension, all-terrain tires, and an engine guard to enhance its off-road capabilities. Despite being a kei-car, it successfully completed the entire rally course of over 2,000 km, which included flat dirt and muddy roads, supporting the team throughout.Mitsubishi Motors’ special website for Tokyo Auto Salon 2025 (in Japanese only)www.mitsubishi-motors.co.jp/carlife/autosalon/tas2025/Triton Custom Contest special website (in Japanese only)www.mitsubishi-motors.co.jp/carlife/autosalon/tcc2024/About Mitsubishi MotorsMitsubishi Motors Corporation (TSE:7211) — a member of the Alliance with Renault and Nissan — is a global automobile company based in Tokyo, Japan, which has about 28,000 employees and a global footprint with production facilities in Japan and the ASEAN region. Mitsubishi Motors has a competitive edge in SUVs, pickup trucks and plug-in hybrid electric vehicles, and appeals to ambitious drivers willing to challenge convention and embrace innovation. Since the production of our first vehicle more than a century ago, Mitsubishi Motors has been a leader in electrification — launched the i-MiEV, the world’s first mass-produced electric vehicle in 2009, followed by the Outlander PHEV, the world’s first plug-in hybrid electric SUV in 2013. With a target of increasing the sales ratio of electrified vehicles to 100% by 2035, Mitsubishi Motors will deliver models that embody Mitsubishi Motors-ness and contribute to the realization of a carbon-neutral society.For more information on Mitsubishi Motors, please visit the company's website at www.mitsubishi-motors.com/en/ Copyright 2025 JCN Newswire via SeaPRwire.com.
‘Toyota Woven City,’ a Test Course for Mobility, Completes Phase 1 Construction and Prepares for Launch
LAS VEGAS, NV, Jan 7, 2025 - (JCN Newswire via SeaPRwire.com) - At CES 2025, Toyota Motor Corporation ("Toyota") announced the completion of Phase 1 construction of Toyota Woven City ("Woven City"), its test course for mobility. The launch of Phase 1 is planned for fall 2025 or shortly thereafter.Toyota first announced its transformation into a mobility company at CES 2018 and, at CES 2020, unveiled the Woven City concept being developed in collaboration with Woven by Toyota ("WbyT") to demonstrate Toyota's long-term commitment to shaping the future of mobility.Woven City has made steady progress since its groundbreaking ceremony on February 23, 2021, at the former site of Toyota Motor East Japan's ("TMEJ") Higashi-Fuji Plant in Susono City, Shizuoka Prefecture, Japan. Construction of Phase 1 buildings―the initial area for co-creation activities―was completed in October 2024. Preparations for the official launch are now underway.Woven City's Phase 1 has also previously been recognized for its environmentally conscious and human-centric design aimed at enhancing people's overall quality of life. It earned Japan's first LEED for Communities* Platinum certification, the system's highest rank.Alongside Phase 1 preparations, renovation of a former TMEJ Higashi-Fuji Plant facility into a manufacturing hub for Woven City is underway, and site preparation work for Phase 2 has commenced. Insights from Phase 1 will help refine plans for Phase 2 and future phases, and continually enhance the test course's functionality.Woven City is a test course for mobility where "Inventors" who share a commitment to working "for someone other than themselves" can develop, test, and validate innovative products and services. These inventors include Toyota and Toyota Group companies, such as WbyT, as well as external companies, startups, and individual entrepreneurs. By leveraging Toyota's decades-long manufacturing expertise and WbyT's software capabilities, Woven City offers a unique environment equipped with the tools and services needed to tackle societal challenges and create future-focused value. Through collaboration among inventors and feedback from residents and visitors, Woven City aims to drive innovation and shape a better tomorrow.The inventors of Woven City who have been confirmed so far are as follows.InventorsDaikin Industries, Ltd.Manufacturing, sales and after-sales services of air conditioning products, fluorochemical products, etc.Testing "pollen-free spaces" and "personalized functional environments"DyDo DRINCO, INC.Manufacturing and sales of soft drinks and other beverages, etc.Creating new value through innovative vending machine conceptsNISSIN FOOD PRODUCTS CO., LTD.Manufacturing and sales of instant noodles and related products, etc.Creating and evaluating food environments to inspire new 'food cultures'UCC Japan Co., Ltd.Regional headquarters of Japanese operating companies engaged in coffee manufacturing and salesExploring the potential value of coffee through futuristic cafe experiencesZoshinkai Holdings Inc.Comprehensive education services offering correspondence education and classroom programsLeveraging data to realize innovative educational methods and new learning environmentsAlphabetical order as of January 7, 2025Woven City is also in continued discussions with previously announced companies such as ENEOS Corporation, Nippon Telegraph and Telephone Corporation (NTT), and Rinnai Corporation.External startups, entrepreneurs, universities and research institutions are also scheduled to be invited to Woven City through an accelerator program, starting in summer 2025.Residents and visitors will play an equally vital role alongside inventors in Woven City. Known as 'Weavers,' these individuals share a passion for the 'expansion of mobility' and a commitment to building a more flourishing society. Through their participation in co-creation activities, Weavers will contribute to realizing the full potential of Woven City.At the official launch of Woven City, starting in fall 2025 or thereafter, approximately 100 residents―primarily Toyota and WbyT staff and their families―are expected to participate in co-creation activities as the first residents. The community will then gradually expand to include external inventors and their families. Phase 1 is projected to accommodate around 360 residents, with the total population, including Phase 2 and subsequent phases, expected to reach approximately 2,000. Initially, visitors will be limited to related parties, with plans to welcome the general public to participate as Weavers in co-creation activities starting in FY2026 or thereafter.Woven City also serves as a test course for Toyota's transformation into a mobility company. Together, Toyota and WbyT aim to redefine mobility, expanding its scope beyond transportation to encompass the movement of people, goods, information, and energy for the benefit of individuals and society. Designed as a human-centered city, Woven City places the people who gather there―Inventors and Weavers―at its center to unlock new possibilities in the shared pursuit of "Well-being for All". With an eye on expanding mobility from land, sea, and air to space, WbyT also announced an investment in Interstellar Technologies Inc. and will leverage Toyota's expertise to support the mass production of rockets.Woven City Phase 1 Basic InformationAddress1117 Mishuku, Susono City, Shizuoka, Japan (Former site of the TMEJ Higashi-Fuji plant)Site AreaApprox. 50,000 sq. m (approx.708,000 sq. m in total in the future)Main TimelineJanuary 7, 2020: Concept announced at CES 2020February 23, 2021: Phase 1 Groundbreaking Ceremony. Start of site preparation work in March 2021October 10, 2022: Phase1 Safety Prayer Ceremony. Start of building work for Phase 1 in November 2022October 31, 2024: Completion of Phase 1 constructionStarting in Fall 2025 or thereafter: Phase 1 official launchResidentsFrom fall 2025 or thereafter, Toyota and Toyota-related personnel will begin to move in, and in Phase 1, a total of approximately 360 people are scheduled to live there (in the future, the number of residents is expected to expand to 2,000 people in all areas)*LEED is an acronym for Leadership in Energy and Environmental Design and refers to a system for evaluating the environmental performance of buildings and cities operated by the U.S. Green Building Council. Woven City was certified in March 2023.About Woven by ToyotaWoven by Toyota, a part of the Toyota Group, is challenging the current state of mobility through human-centric innovation and empowering mobility transformation. Through our AD/ADAS technology, our automotive software development platform Arene OS, our mobility test course Toyota Woven City, and Toyota's growth fund, Woven Capital, we are pioneering the movement of people, goods, information, and energy, weaving a future of enhanced safety, connectivity and well-being for all. Copyright 2025 JCN Newswire via SeaPRwire.com.
Elucidation of part of the Mechanism by which Lecanemab Slows the Progression of Alzheimer’s Disease
TOKYO, Jan 7, 2025 - (JCN Newswire via SeaPRwire.com) - A collaborative research group led by Professor Kenjiro Ono of the Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, and Eisai Co., Ltd., used a newly developed measurement system for lecanemab-associated amyloid-β protofibrils (Lec-PF) to demonstrate that the concentration of Lec-PF in human cerebrospinal fluid is elevated in patients withAlzheimer's disease at all stages, from mild cognitive impairment to mild and severe dementia, compared with non-Alzheimer's disease controls. Furthermore, this research identified that the concentration of Lec-PF in cerebrospinal fluid is significantly correlated with biomarkers reflecting neurodegeneration.Lecanemab (*1) is a unique dual acting antibody that selectivity binds to amyloid-β protofibril (PF *2) in addition to removing plaque, and is a treatment for patients with mild cognitive impairment and mild dementia due to Alzheimer’s disease (AD *3) (collectively referred to as early AD). The results of this study suggest that PF which is captured by lecanemab (Lec-PF), is present in the cerebrospinal fluid of patients with Alzheimer’s disease, and that Lec-PF is a highly toxic pathological protein that causes neurodegeneration. This research has revealed part of the mechanism by which lecanemab demonstrates its effect of slowing the progression of Alzheimer’s disease.Based on these findings, it may be possible in the future to measure Lec-PF concentration in cerebrospinal fluid before and afterlecanemab treatment to assess the treatments efficacy. In addition, because the concentration of Lec-PF in cerebrospinal fluid correlates well with neurodegenerative markers such as total tau (*4) and neurogranin (*5), it is expected that these findings could also be useful in predicting the prognosis of Alzheimer’s disease patients.This research was published in the online version of the international academic journal Annals of Neurology at 18:30 on January 6, 2025 (US Eastern Standard Time).Research Background and ObjectivesThe amyloid cascade hypothesis is a leading theory regarding the cause of AD, which states that amyloid beta (Aβ) (*6) abnormally aggregates outside of neuron, followed by the formation of tau neurofibrillary tangles, which causes damage to neuron and leads to the onset of the disease. PF is more neurotoxic than amyloid fibrils and plaque, which are the final stages of abnormal aggregated Aβ, and it is believed that PF may cause neurodegeneration (reference: Amin L and Harris DA. 2021). Lecanemab is an anti-PF antibody that has been used in medical practice since 2023 as a treatmentfor early AD. However, there have been no previous reports of measuring PF concentrations in human biological samples, and the profiles of PF, which is the therapeutic target of lecanemab, across the full AD continuum have not yet been understood.In this study, the research group used a newly developed, highly sensitive Lec-PF measurement system to measure the concentration of Lec-PF in human cerebrospinal fluid (CSF) in subjects with preclinical AD (*7), mild cognitive impairment due to AD, and AD dementia, as well as patients with SNAP (suspected non-AD pathophysiology) (*8) and people with normal cognitive function, and analyzed the association between Lec-PF and Aβ40, Aβ42, phosphorylated tau (p-tau) 181 (*9), p-tau 217, total tau, and neurogranin.Summary of Research ResultsThe Lec-PF CSF concentration was significantly higher in patients with mild cognitive impairment or dementia due to AD (MCI+,AD+ groups in Figure 1) than in those with normal cognitive function (YNC and AMC groups in Figure 1).Correlation analysis was conducted between the concentration of Lec-PF in cerebrospinal fluid and other cerebrospinal fluid markers (Aβ42, Aβ42/40 ratio, p-tau 181, p-tau 217, total-tau, neurogranin).Future DevelopmentsMeasuring the Lec-PF concentration in CSF before and after lecanemab treatment may be useful in assessing the efficacy of lecanemab treatment. In addition, because the concentration of Lec-PF in CSF correlates well with neurodegenerative markers, it may also be useful for predicting the prognosis of AD patients.This research was supported by the Japan Agency for Medical Research and Development (AMED) Research and Development Grants for Dementia (Grant No. 22dk0207053), Grants-in-Aid for Transformative Research (Grant No. 23H03850), and Grants-in-Aid for Scientific Research (Grant Nos. JP19k07965, JP22k07514).Fig. 1 Cerebrospinal fluid lecanemab-related amyloid protofibril (CSF Lec-PF) concentrations according to clinical diagnosis and amyloid positivity/negativityDescription of Figure 1Boxes in boxplots indicate interquartile ranges andhorizontal lines indicate medians.Abbreviations for each group: YNC (young normal control amyloid-negative), AMC (age-matched control amyloid-negative), CI- (cognitively impaired amyloid-negative), CU+ (cognitively unimpaired amyloid-positive), MCI+ (mild cognitive impairment amyloid-positive), AD+ (AD dementia amyloid- positive), CSF (cerebrospinal fluid)*p < 0.05Figure 2 Correlation between cerebrospinal fluid markers and cerebrospinal fluid lecanemab- related amyloid protofibrils (CSF Lec-PF)Description of Figure 2The black line and the red line indicate the 95% confidence interval (CI) of the Spearman correlation coefficient between CSFLec-PF and each cerebrospinal fluid marker in the entire subject group and in the amyloid-positive subject group, respectively. The black and red dots indicate the median value of the Spearman correlation coefficients. A large discrepancy between the black and red lines reflects the significant impact of the status of being either Aβ positive or negative.In this analysis, in all subjects (black line), the correlation coefficients between CSF Lec-PF and all measured biomarkers, namely Aβ42, Aβ42/40 ratio, p-tau 181, p-tau 217, total-tau, and neurogranin, were all 0.2 or higher, indicating significant correlations between CSF Lec-PF and these biomarkers.In the amyloid-positive group (red line), the Spearman correlation coefficients were 0.634 (CI: 0.409- 0.786) between CSF Lec-PF and CSF total-tau, and 0.434 (CI: 0.260-0.581) between CSF Lec-PF and CSF neurogranin, respectively, indicating a strong correlation between CSF Lec-PF and the two biomarkers. On the other hand, the correlations between CSF Lec-PF and the brain Aβ accumulation biomarkers, CSF Aβ42 and the CSF Aβ42/40 ratio, were both relatively low. This indicates that the amount of CSF Lec-PF is more strongly associated with neurodegeneration than the accumulation of Aβ in the brain.Published PapersJournal name: Annals of NeurologyPaper title: Lecanemab-associated amyloid-β protofibril in cerebrospinal fluid correlates with biomarkers of neurodegeneration in Alzheimer’s disease (Cerebrospinal fluid (CSF) lecanemab-associated amyloid protofibril concentrations correlate well with neurodegenerative biomarkers in AD)Authors: Moeko Noguchi-Shinohara, Kazuyoshi Shuta, Hidetomo Murakami, Yukiko Mori, Junji Komatsu, Chizuru Kobayashi, Steven Hersch, Kanta Horie, Kenjiro Ono (Moeko Shinohara, Kazuyoshi Shuta, Hidetomo Murakami, Yukiko Mori, Junji Komatsu, Chizuru Kobayashi, Steven Hersch, Kanta Horie, Kenjiro Ono)Date of publication: January 6, 2025 (US Eastern Standard Time). DOI: 10.1002/ANA.27175Terminology(1) LecanemabLecanemab is a treatment for early Alzheimer’s disease (AD) and is an antibody that selectively binds to amyloid protofibrils, which are considered to be particularly neurotoxic among amyloid beta aggregates. In September 2023, lecanemab was approved in Japan as a treatment for slowing progression of mild cognitive impairment and mild dementia due to AD.(2) ProtofibrilsProtofibrils are large Aβ aggregated soluble species of 75-5000 kDa, and are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.(3) Alzheimer’s diseaseAD is a progressive brain disorder that gradually impairs memory and cognitive ability, eventually leading to a condition knownas dementia that interferes with daily life. In the brains of patients with AD, changes such as structures called senile plaques that form due to the accumulation of a substance called amyloid-β, abnormal tangles of neurofibrillary changes (neurofibrillarytangles caused by the abnormal phosphorylation of tau protein), and loss of neurons are observed. These changes progress over a long period of time.(4) Total TauTau protein is a type of microtubule-associated protein that is found in large amounts in neurons and glial cells in the central and peripheral nervous systems. In neurodegenerative diseases, including AD, the concentration of total tau in CSF increases as the disease progresses. For this reason, total tau is used as a marker of neurodegeneration.(5) NeurograninNeurogranin is a neuron-specific postsynaptic protein that is found in large amounts in areas such as the cerebral cortex andhippocampus. Neurogranin in CSF is used as a marker for neurodegeneration.(6) Amyloid beta (Aβ)Amyloid-β (Aβ) includes peptides generated by the cleavage of amyloid precursor protein (APP) by β- secretase and γ-secretase, such as Aβ40, which ends at position 40 of the C-terminus, and Aβ42, which ends at position 42 of the C-terminus Aβ42 inparticular has a high aggregating tendency, and in AD, there is a decrease in Aβ42 concentration in CSF and an increase in the Aβ40/42 ratio, which is known to show a strong correlation with the amount of amyloid accumulation measured by amyloid PET testing.(7) Preclinical Alzheimer’s diseaseA stage of AD before cognitive impairment has occurred.(8) SNAP (suspected non-Alzheimer’s disease pathophysiology)SNAP is an abbreviation for suspected non-AD pathophysiology. The term refers to a condition that involves neurodegeneration similar to that seen in AD, despite normal results of amyloid PET scans, CSF Aβ40/42 ratio, and CSF Aβ42. In this study, the CI- group (cognitively impaired amyloid-negative group) in Figure 1 corresponds to patients with SNAP.(9) Phosphorylated tauThe accumulation of phosphorylated tau protein is considered to be a cause of neurofibrillary tangles, which are pathological traits of AD. Many phosphorylation sites are known in tau protein, among which tau protein phosphorylated at threonine residue 181 (p-tau 181) and tau protein phosphorylated at threonine residue 217 (p-tau 217) are frequently seen in AD. For this reason, p-tau 181 and p-tau 217 in CSF are used as biomarkers for AD.ReferenceAmin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. DOI:10.1038/s41467-021-23507-zContact for InquiriesRegarding research content Kanazawa University Professor Kenjiro OnoTEL: +81-(0)76-265-2292Email: onoken@med.kanazawa-u.ac.jpAssociate Professor Moeko Shinohara TEL: +81-(0)76-265-2292Email: m-nohara@med.kanazawa-u.ac.jpEisai Co., Ltd.Kanta HorieE-mail: kanta_horie@eisai.comPublic Relations OfficerGeneral Affairs Section, General Affairs Division, Medical, Pharmaceutical and Health Sciences Administration Department, Kanazawa UniversityRina YamadaTEL: +81-(0)76-265-2109E-mail: t-isomu@adm.kanazawa-u.ac.jpEisai Co., Ltd. PR Department TEL: +81-(0)3-3817-5120 Copyright 2025 JCN Newswire via SeaPRwire.com.
Toyota to Share Progress on Woven City at CES 2025
Toyota City, Japan, Jan 6, 2025 - (JCN Newswire via SeaPRwire.com) - Toyota Motor Corporation will make a presentation on Woven City at the CES 2025 press conference.The press briefing will be live streamed on this webpage. Video from the presentation will be available on-demand after the live stream.Live stream detailsDate / TimeMonday, January 6, 2025, 13:00 p.m. (Pacific Standard Time)Tuesday, January 7, 2025, 6:00 a.m. (Japan Standard Time)*The starting time is subject to change depending on the circumstances.Toyota attendeeAkio Toyoda, Chairman of the Board of Directors (Representative Director)Event detailPresentationRelated Content:CES 2025 Teaser: Welcome to Woven CityToyota Times: Akio Returns to CES―Mark the Calendar for January 7! Copyright 2025 JCN Newswire via SeaPRwire.com.
Mazda to build Module Pack Plant for Cylindrical Lithium-ion Batteries for Automotive Use in Iwakuni City, Yamaguchi Prefecture
HIROSHIMA, Japan, Jan 6, 2025 - (JCN Newswire via SeaPRwire.com) - Mazda Motor Corporation (Mazda) has announced that it will build a new module pack plant for automotive cylindrical lithium-ion battery cells in Iwakuni City, Yamaguchi Prefecture, Japan. The new plant will produce modules and packs of automotive cylindrical lithium-ion battery cells procured from Panasonic Energy Co., Ltd. (Panasonic Energy). The completed battery packs will be installed in Mazda's first battery EV that uses a dedicated EV platform and will be manufactured at Mazda's vehicle plant in Japan. The annual production capacity is planned to be 10 GWh.Under the 2030 Management Policy, Mazda is steadily preparing for electrification technologies based on the multi-solution strategy that provides a variety of technological options to meet customer needs and regulatory changes, in order to contribute to solving the social issue of curbing global warming. In the field of batteries, one of the key components of electrified vehicles, the company signed an agreement with Panasonic Energy in May 2023 to procure cylindrical lithium-ion batteries for automotive use, and in September 2024, the plan to expand battery production and technology development through this collaboration was certified by the Ministry of Economy, Trade and Industry (METI) as a "plan to ensure stable supply of storage batteries. Based on the plan, Mazda will provide its customers with its unique battery-electric vehicles that offer a high level of design, convenience and driving range by using the battery module packs produced at the new plant. The plant will also contribute to local employment and economic development.Mazda will continue to evolve "Joy of Driving" based on the value of "Radically Human" toward the year 2030, and will aim to deliver "Joy of Living" by creating exciting mobility experiences in our customers' daily lives.About Mazda’s Brand Essence “Celebrate Driving”Mazda's Brand Essence is “Celebrate Driving”. “Celebrate Driving” delivered by Mazda is not just about driving performance. Choosing a Mazda prizes the owner with confidence and pride. Driving a Mazda leading up to urge to take on new challenges. Not just our products but every encounter with Mazda evokes the emotion of motion and makes customers' hearts beat with excitement. All of these are contained in our brand essence of “Celebrate Driving”. For more information, visit www.mazda.com. Copyright 2025 JCN Newswire via SeaPRwire.com.
泛远国际附属收购美国物流公司30%股权
香港, 2025年1月6日 - (亚太商讯 via SeaPRwire.com) - 泛远国际控股集团有限公司（上市编号：2516，下称'泛远国际'；连同其附属公司，统称'泛远国际'或'本集团'）欣然宣布，本集团间接全资附属公司Ingrun Holdings Limited（'Ingrun'）于2025年1月3日交易时段后以现金代价635,318.4美元（约493万港元*）收购美国物流公司Advanced Logistics Solutions LLC（'Advanced Logistics'）之30%股权。此次收购有助提升本集团在美国乃至海外物流网络的竞争力，为布局全球市场奠定坚实基础。根据收购协议，Ingrun向Hi5s, LLC（美国犹他州成立的有限公司）及Hard 8, LLC（美国佛罗里达州成立的有限公司）分别收购其各自持有Advanced Logistics之15%公司股权，现金代价合共为635,318.4美元（约493万港元*），将以本集团的内部资源拨付。于交割完成后，本集团之间接全资附属公司Ingrun将持有Advanced Logistics合共30%之股权，并将其视作为本集团之联营公司。早于权益收购前， Advanced Logistics已是本集团在美国的供应商，其经营集装箱货运站并于包裹运抵美国机场后为本集团提供揽收、分拣及仓库及清关服务，近年双方往来交易亦屡创新高，交易规模由1,000万元人民币逐年递增至6,000万元人民币，伙伴关系紧密稳固。收购Advanced Logistics部分股权是本集团深入海外市场版图，尤其是美国市场、提升海外物流网络供应链的透明度和成本效益的重要举措。Advanced Logistics在Type 86（T86）清关和集装箱货运站（CFS）仓储服务上具备显著优势，包括其在美国拥有丰富T86清关经验及专业团队，经收购后能为本集团提供高效、顺畅的跨境电商清关流程，减少通关时间及成本，确保包裹顺利进入美国市场；Advanced Logistics亦在美国主要港口设有CFS仓库，其不仅承担着自接收、分拣到配送运输等重要物流功能，亦能作为海关监管仓库实现更精确的货物监控和合规性审查，此等核心优势能完善本集团于美国的物流网络供应链，为跨境电商包裹提供高效完善的管理及整合服务，更大大降低潜在的清关风险，有效提升整体物流供应链的透明度和控制力。本集团作为知名的跨境电子商务物流服务供应商，提供端到端物流服务及国际货运代理等服务，经营中美、南美等多条专线，同时拥有在美国七大口岸的操作能力。本次收购Advanced Logistics部分权益旨在加强于美国市场的物流供应链布局，以把握美国物流市场的发展机遇。根据美国供应链管理专业协会2024年11月最新发布的LMI指数（物流经理人指数）是58.9，为两年来的最高水平，总体指数亦实现连续十一个月上升，反映美国市场需求上升，物流行业正重回稳固水平，市场蕴藏机遇，而规模化及高效的物流网络更有望从中突围而出。是次股权收购为本集团在美跨境物流业务的拓展提供优厚条件，展现集团扩展跨境电商物流业务版图的决心，亦有助于加快融入目标地区市场，增加市场份额及业务营收。泛远国际控股集团有限公司主席、行政总裁兼执行董事王泉先生表示：'年内集团频传佳音，此次收购Advanced Logistics部分权益是继泛远国际接连获颁'4A级物流企业'及'大湾区新质生产力企业大奖 - 运输，货运，物流及供应链奖'后又一利好消息。这一举措不仅增强我们的市场竞争力，也进一步完善海外业务部署，极大提高服务能力。我们将与Advanced Logistics优势互补、高度协同，共同为集团在美国业务的开发与拓展努力。我们相信，此次收购将为股东和投资者带来诸多裨益，可望创造更大价值。'*按概约汇率1.0美元兑7.76港元换算有关泛远国际控股集团有限公司（股份代号：2516.HK）泛远国际控股集团有限公司于2023年12月在香港联交所主板挂牌上市，为中国知名的跨境电子商务物流服务供应商，主要提供端到端跨境配送服务、货运代理服务以及其他物流服务，致力打造稳、快、优的跨境电子商务物流服务体系。本集团作为中国（杭州）跨境电子商务综合试验区首批试点企业，拥有创新的自研物流运输系统，采用直营网点模式，网点遍布中国主要贸易中心，尤其聚焦于长江三角洲及粤港澳大湾区。本集团设有30多个境内网点，1,100多家供应商网络，服务覆盖全球超过220多个国家和地区，向客户提供多项灵活可靠的跨境配送选项及定制化供应链解决方案。 Copyright 2025 亚太商讯 via SeaPRwire.com.
美高域携手盖睿科技 AI赋能助力打造香港医疗新模式
香港, 2025年1月6日 - (亚太商讯 via SeaPRwire.com) - 近期，美高域集团有限公司Microware Group Limited（1985.HK，简称'美高域（Microware）'）与盖睿科技（GAREA TECH）在香港签订合作协议，双方将充分利用各自优势，共同推动香港医疗市场的数智化发展和AI布局。此次合作将覆盖香港3000家社区诊所，打造香港智慧医疗健康服务中心。作为香港信息科技行业的领导者之一，美高域成立已达40年历史，每年服务2000+客户，服务香港前百大上市公司中60%的企业，为80个政府单位提供服务。多年来，美高域致力于将AI技术与具体应用场景融合，为各行业提供智能化、高效率的AI解决方案，并自研新一代企业级AI生产力平台。目前，美高域的业务范围已涵盖智慧医疗、智算中心等前沿科技产业。此次与盖睿科技的合作，不仅标志着美高域在探索医疗数智化发展的又一项重大进展，亦体现了其在AI领域不俗的技术实力，市场认可度持续增强。盖睿科技是全球领先的数字基础医疗整体解决方案提供商，致力于基础医疗数字化转型与智慧健康服务的创新。双方此次合作，美高域将凭借其自身在AI领域的技术优势，赋能盖睿科技。双方将共同合作开发智慧医疗平台，为香港医疗市场提供包括一体化全科医生工作站、病历翻译、多语种实时语音转录、多语种实时翻译、病历记录生成、个人专属病历数据库和高效AI问诊工具等在内的智慧医疗一体化解决方案，提高问诊全流程效率和医疗服务质量，实现AI+医疗的深度融合。随着人口老龄化的加速，香港基层医疗系统正不断致力于将医疗健康架构的焦点从治疗转向预防疾病，这对基层医疗服务提出了更高的要求。2022年底，香港特区政府推出《基层医疗健康蓝图》，规划进一步提升基层医疗健康系统，在此背景下美高域与盖睿科技的合作应运而生。藉助美高域先进的AI技术，双方能够为患者带来更加便捷和定制化的医疗体验，从而提高医疗服务的精准度与效率，推动医疗行业的数字化转型。未来，美高域和盖睿科技还计划在更多领域展开深度合作，以进一步拓宽智慧医疗的应用场景，推动医疗行业的持续发展与创新。美高域集团董事会主席王广波表示，'集团将持续深化技术应用，拓展跨行业和跨区域的覆盖面，我们坚信，随着合作的深入，我们能够为香港乃至全球的医疗健康领域带来革命性的变化，让更多人享受到由人工智能赋能的优质医疗服务，共同迈向一个更加智能、更加健康的未来。' Copyright 2025 亚太商讯 via SeaPRwire.com.
蜜雪冰城拟香港上市 业绩如虹释放飞轮效应
香港, 2025年1月3日 - (亚太商讯 via SeaPRwire.com) - 2024年，随着香港市场气氛转好，新股发行持续回暖，香港作为上市目的地的吸引力与日俱增，全年共录得71宗IPO。得益于美的集团、顺丰控股、地平线等多个大型新股上市所带动，香港年度募资总额逾800亿港元，排名全球第四。中国证监会鼓励内地龙头企业来港上市以及中国内地计划适度地宽松货币政策利好推动下，预期2025年将陆续有大型企业来港上市。1月1日，中国及全球现制饮品龙头蜜雪冰城股份有限公司（下称「蜜雪冰城」或「公司」）更新港股招股书，IPO计划顺利推进中，美银、高盛、瑞银担任联席保荐人。门店数量跻身全球第一 盈利蒸蒸日上自1997年成立至今，蜜雪冰城一直聚焦为广大消费者提供单价约6元人民币（约1美元）的高质平价的现制果饮、茶饮、冰淇淋和咖啡等产品。根据灼识咨询报告，按照截至2024年9月30日的门店数计，蜜雪冰城已超越星巴克，成为中国及全球第一的现制饮品企业。蜜雪冰城采用利益与共的加盟模式和高度数字化的运营体系，令其打造了健康的加盟门店网络，业务规模迅速扩张。2024年首九个月，公司门店净增超过7,700家，期末门店数突破45,000家，覆盖中国及海外11个国家（包括印尼、越南、马来西亚、泰国、菲律宾、柬埔寨、老挝、新加坡、澳大利亚、韩国及日本），且海外市场以一带一路国家为主。截至2024年9月30日，蜜雪冰城在中国内地以外拥有约4,800家门店。门店数量高歌猛进的同时，蜜雪冰城的门店表现也稳步向好。2024年首九个月，公司门店网络实现出杯量约71亿杯；终端零售额人民币449亿元，平均单店日均终端零售额为人民币4,184.4元。抱定长期主义 「增长飞轮」加速向前围绕可持续发展战略，蜜雪冰城一直坚持长期主义理念，业绩保持着高速增长，形成良性循环的增强回路，释放飞轮效应，演绎「大象起舞」的价值跃升轨迹。近年来，在巨大的规模基础上，蜜雪冰城实现了强劲的增长、优异的盈利水平和充裕的现金流。2024年首九个月，公司录得收入约人民币187亿元，同比增长超过21%；净利润约人民币35亿元，同比增长超过42%，约是收入增速的两倍。同期，公司降本增效显著，利润率进一步提升，录得毛利率32.4%、净利率18.7%。收入和利润的双增，也为蜜雪冰城带来了源源不断的现金流，持续创造经营活动现金流量净流入，2021年、2022年、2023年以及2024年首九个月分别为人民币17亿元、24亿元、38亿元及51亿元，为公司的高质量发展奠定坚实的资本基础。放眼而望，现制饮品市场堪称万亿蓝海，拥有相当广阔的发展空间。根据灼识咨询的报告，以终端零售额计，中国现制饮品市场的规模预计在2028年达到约1.2万亿人民币，2023年至2028年的复合年增长率为17.6%。过去二十多年来，蜜雪冰城打造了强大和成功的品牌，并实现滚雪球式的复利增长，未来也有望继续受惠于行业发展红利。凭借跨地域和跨品类的规模化拓展，蜜雪冰城把握全球机遇，打开了充满想象力的长期增长空间。通过打造大规模的极致高效供应链基础设施、建设全民品牌和拓展加盟门店网络，公司也将继续推动规模化、可持续的成长，巩固龙头地位，未来表现更值得期待。 Copyright 2025 亚太商讯 via SeaPRwire.com.
沿着一带一路卖饮料 雪王已进入海外11国
香港, 2025年1月2日 - (亚太商讯 via SeaPRwire.com) - 经过多年的爆发式增长后，现制饮品市场的竞争依旧激烈。在众多品牌中，蜜雪冰城的表现引起了市场的关注。作为中国及全球最大的现制饮品龙头（以截至2024年9月30日门店数计），蜜雪冰城在规模、供应链、品牌力等方面构筑了良好的竞争优势，稳居行业领先地位。1月1日，蜜雪冰城更新港股A1招股书，其业务表现又有哪些新的突破？国内国外稳步扩张 门店数跃居全球第一随着行业度过跑马圈地的高速扩张期，如何挖掘新的业务增量，已成为头部品牌们面临的一道必答题。蜜雪冰城通过聚焦下沉与出海这两大极具发展潜力的市场，稳步推进其门店扩张战略，捕捉市场发展机遇。国内市场方面，蜜雪冰城凭借广泛的门店网络，持续渗透三四线以及乡镇下沉市场。截至2024年9月30日，公司在中国内地的门店数超过40,000家，覆盖超过300个地级市、1,700个县城和4,900个乡镇，其中超过23,000家位于三线及以下城市，占比达到57.2%。在国内稳居市场鳌头的同时，蜜雪冰城积极响应一带一路倡议，积极进军海外市场。截至2024年9月30日，公司在中国内地以外拥有约4,800家门店，包括印尼、越南、马来西亚、泰国、菲律宾、柬埔寨、老挝、新加坡、澳大利亚、韩国和日本11个国家以及香港和澳门地区。其中，越南和印尼两国开店数量分别超过1,300家及2,600家，成为公司国际化布局的主力。得益于国际国内的同步发力，2024前九个月，蜜雪冰城净增门店数超过7,700家（相较于2023年底）。截至2024年9月30日，公司门店数超过45,000家，就门店数量而言，蜜雪冰城已超越星巴克，成为中国以及全球最大的现制饮品企业。门店表现亮眼 业绩高基数之上延续增长值得一提的是，蜜雪冰城并非单纯追求门店数量的增长，而是经过深入研究市场需求、消费趋势之后的精心布局，这使其新开门店能够快速站稳脚跟，为可持续发展奠定坚实基础。从2024年前9个月的平均单店日均终端营业额看，2024年新开业的门店平均单店日均终端营业额表现不输老店。同时，蜜雪冰城老店的运营表现也十分稳健。得益于精准的市场洞察、持续的产品创新、高效的供应链管理以及强大的市场口碑，老店（2021年或之前开业门店）的平均单店日均终端营业额在2021年至2023年期间仍呈现年化4%以上的增长，2023年及以前开业的门店在2024年前九个月的平均单店日均终端营业额均超过2023年全年的水平。在高效门店扩张战略的支持下，蜜雪冰城在过往较高业绩基数的基础上，依然实现了收入、利润的双双增长，盈利能力进一步提升。2024年前9个月，实现收入人民币187亿元，同比增长超过21%；净利润人民币35亿元，同比增长超过42%。毛利率为32.4%，同比提升2.7个百分点；净利率为18.7%，同比提升2.8个百分点。中长期看，随着城镇化的持续推进以及居民收入水平的提升，现制饮品消费数量和消费能力将不断增长，为行业发展提供广阔的市场空间。蜜雪冰城以高性价比产品俘获用户心智，国内市场持续深耕下沉市场，将进一步巩固其领先优势，同时，国际化战略的深入推进也将为公司打造新的增长引擎。在国内国际市场共同驱动下，蜜雪冰城有望释放更大的增长弹性。 Copyright 2025 亚太商讯 via SeaPRwire.com.
纵横公关集团成立30周年 昂首迈向璀璨新里程
香港, 2025年1月2日 - (亚太商讯 via SeaPRwire.com) - 纵横公共关系顾问集团 (简称「纵横公关集团」或「集团」) 今日欣然宣布正式迈入集团成立30周年的辉煌时刻。为纪念这一里程碑，集团推出各种活动以示庆祝，其中包括已于2024年底圆满落幕的30周年标志设计比赛。通过设计比赛的激烈角逐，一款印有「30」数字和地球元素的标志脱颖而出，它象征着集团全球布局之专业团队，以及为全球客户提供卓越服务的坚定承诺。这款标志将于2025 年起广泛应用于集团的各种宣传和推广材料，成为集团30周年志庆的标志性符号。2025年首个工作日，纵横公关集团以别出心裁的庆祝活动拉开周年志庆的序幕，为同事们准备了珍珠奶茶、茶点以及舒适的按摩服务，旨在为新的一年注入活力。纵横公关集团主席及创办人曾立基在庆典上表示：「珍珠的璀璨光泽，象征着时间的沉淀与磨砺，正如纵横公关集团经历30年来的蓬勃发展。在过去30年间，我们见证了全球政经格局的复杂多变，面对重重挑战，我们始终坚韧不拔。而正是这份韧性和适应能力，让我们不仅跨跃挑战，更从香港一间本地公司，跻身于亚太地区顶尖的公关集团之列，拥有旗下成员公司20家。我们的业务范畴也从最初专注的金融服务，扩展到更为全面的综合解决方案，使我们在瞬息万变的市场中独树一帜。」纵横公关集团一直致力于业务据点和范畴的扩展，同时坚守提供卓越服务和追求进步的核心精神。2024年，集团迈向研究领域的重要一步，由在研究范畴的专精学者带领，专注于环境、社会和管治(「ESG」)议题的研究。凭借团队的学术积累和对全球趋势的深刻洞察为客户提供更具针对性的专题调研，并据此制订解决方案。集团认为，这一新服务不仅能满足现有客户的需求，更能吸引更多潜在客户，推动集团业务向多元化发展。集团的创意服务和数位内容创作旗舰Strategic DigitaLab(简称「SDL」) (www.strategicdigitalab.com)自2017年成立以来，不断引领创新潮流。2024年，SDL更是致力于重塑品牌形象，凭借其卓越的叙事能力，在多元平台全面发力，成功带动客户寻求高效、大规模的内容创作服务，以满足、启发和鼓动目标受众。通过共享创意和数位能力，SDL使集团在瞬息万变的时代中占据先机，充分满足了各大客户的多样化需求。而为了配合在南半球的客户需要，集团于2024年全面收购了Financial & Corporate Relations Pty Limited (「FCR」) 。FCR是澳大利亚一家拥有40年历史的顾问公司，专注于投资者、企业及财经传讯领域。集团对这次收购充满期待，相信FCR将为集团带来业务上的全新突破。多年来，集团始终秉持对服务品质的极致追求，也因此收获了超过540个奖项和殊荣，包括亚太区最佳公关集团、最佳公关顾问(亚太区及亚洲)、大中华最佳独立顾问公司、香港最佳公关顾问、亚太区最佳财经公关顾问、最佳危机管理团队及市场领袖大奖等。集团主席曾立基表示：「感谢每一位同事的坚持不懈和团队的合作无间，让我们能够济济一堂共同庆祝30周年这一重要时刻。展望未来，集团将继续在公关领域精益求精，寻求创新，不断提升服务品质，积极拥抱自动化和新科技；为团队提供全面的培训，并积极探索新的业务领域。同时，作为企业公民的坚定倡导者，我们也将继续积极参与公益活动和义务公关工作，为社会贡献我们的力量。」关于纵横公共关系顾问集团 (「纵横公关集团」)纵横公关集团于1995年在香港成立之时以投资者关系服务为核心，至今已发展成为辐射亚太区、服务本地及国际客户的综合公关顾问。集团在亚太区8大据点聘有超过250名公关专才，同时透过分布世界各地的伙伴和PROI Worldwide，在逾165个城市为客户提供一站式综合传讯服务。 欢迎流览网站: www.sprg.asia垂询 纵横财经公关顾问有限公司 温淑贤电话: (852) 2864 4822电邮: eveline.wan@sprg.com.hk网址: www.sprg.asia 香港 | 北京 | 上海 | 广州 | 台北 | 新加坡 | 吉隆玻 | 悉尼 Copyright 2025 亚太商讯 via SeaPRwire.com.
新版国家医保药品目录落地 全球首个IgA肾病对因治疗药物耐赋康(R)纳入报销
上海, 2025年1月2日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀（HKEX 1952.HK）是一家专注于创新药研发、临床开发、制造和商业化的生物制药公司，今日宣布随着《国家基本医疗保险、工伤保险和生育保险药品目录（2024年）》（"国家医保药品目录"）2025年1月1日正式实施，耐赋康(R)（布地奈德肠溶胶囊，NEFECON(R)）将开始执行医保新价格，各地IgA肾病患者将陆续享受医保报销。耐赋康(R)于2024年11月被纳入国家医保药品目录。作为全球首个获得美国食品药品监督管理局（FDA）和欧洲药品管理局（EMA）完全批准的IgA肾病治疗药物，耐赋康(R)于2023年11月通过优先审评程序正式获得中国国家药品监督管理局的批准，用于治疗具有进展风险的原发性IgA肾病成人患者，是中国唯一获得IgA肾病适应症的治疗药物。根据国家医保局要求，耐赋康(R)将于1月开始在北京、上海等各省市执行医保报销，患者可在定点医疗机构或定点药店购药，并享受医保报销价格。国家医保药品目录的正式实施将提升耐赋康(R)的可及性，减轻患者负担，使更多中国IgA肾病患者从这款创新药物中获益。耐赋康(R)全球III期临床试验NefIgArd研究中国人群数据分析显示，耐赋康(R)减少66%的肾功能下降，预估可将疾病进展至透析或肾移植的时间延缓12.8年。凭借创新的作用机制和临床优势，耐赋康(R)已经得到了国内外多个权威治疗指南的推荐，包括被纳入由改善全球肾脏病预后组织（KDIGO）发布的《2024版KDIGO IgA肾病和IgA血管炎临床管理实践指南（公开审查版）》，并被指是迄今为止唯一被证明可以降低致病性IgA和IgA免疫复合物水平的治疗方法。关于耐赋康(R)（NEFECON(R)）耐赋康(R)(NEFECON(R))是布地奈德肠溶胶囊，作为全球首个对因治疗IgA肾病的药物，是靶向肠道黏膜B细胞的免疫调节剂，能减少50%肾功能下降1，在中国人群中能延缓肾功能衰退达66%2，预计将疾病进展至透析或肾移植的时间延缓12.8年3。同时布地奈德首过代谢程度达90%4，具有良好的安全性。耐赋康(R)专为IgA肾病患者研制，每颗胶囊含布地奈德4mg，通过特殊的迟释及缓释双重制剂工艺，将布地奈德靶向释放于回肠末端的黏膜B细胞（包括派尔集合淋巴结），胶囊溶解后，三层包衣微丸持续稳定释放布地奈德，高浓度覆盖整个靶区域，从而减少诱发IgA肾病的半乳糖缺陷的IgA1抗体（Gd-IgA1）产生，进而干预发病机制上游阶段，达到治疗IgA肾病的作用。2019年6月，云顶新耀与Calliditas Therapeutics 签订独家授权许可协议，获得在大中华地区和新加坡开发以及商业化耐赋康(R)的权利。该协议于2022年3月扩展，将韩国纳入云顶新耀的授权许可范围。关于云顶新耀云顶新耀是一家专注于创新药和疫苗研发、临床开发、制造和商业化的生物制药公司，致力于满足亚洲市场尚未满足的医疗需求。云顶新耀的管理团队在中国及全球领先制药企业从事过高质量研发、临床开发、药政事务、化学制造与控制（CMC）、业务发展和商业化运营，拥有深厚的专长和丰富的经验。云顶新耀已打造多款疾病首创或者同类最佳的药物组合，公司的治疗领域包括肾科疾病、感染性和传染性疾病、自身免疫性疾病。有关更多信息，请访问公司网站：www.everestmedicines.com。前瞻性声明本新闻稿所发布的信息中可能会包含某些前瞻性表述，乃基于本公司或管理层在做出表述时对公司业务运营情况及财务状况的现有看法、相信、和现有预期，可能会使用"将"、"预期"、"预测"、"期望"、"打算"、"计划"、"相信"、"预估"、"确信"及其他类似词语进行表述。这些前瞻性表述并非对未来业绩的保证，会受到风险、不确定性及其他因素的影响，有些乃超出本公司的控制范围，难以预计。因此，受我们的业务、竞争环境、政治、经济、法律和社会情况的未来变化及发展等各种因素及假设的影响，实际结果可能会与前瞻性表述所含资料有较大差别。本公司及各附属公司、各位董事、管理人员、顾问及代理未曾且概不承担更新该稿件所载前瞻性表述以反映在本新闻稿发布日后最新信息、未来项目或情形的任何义务，除非法律要求。参考文献1.Lafayette R,et al. Lancet. 2023 Sep 9;402(10405):859-870.2.2023ASN. Oral presentation.3.Jonathan Barratt,et al. 2023 ASN. Poster no. SA-PO886.4.Edsbäcker S,et al. Aliment Pharmacol Ther. 1999 Feb;13(2):219-24. Copyright 2025 亚太商讯 via SeaPRwire.com.
英诺赛科今日上市：氮化镓龙头成长动力充足
香港, 2024年12月31日 - (亚太商讯 via SeaPRwire.com) - 2024年下半年以来，香港资本市场掀起一波上市热潮。从科技新贵到行业巨头，众多内地企业将目光投向香港资本市场。临近岁末，又一细分领域行业龙头登陆港股资本市场。12月30日，英诺赛科（2577.HK）在港上市，掀开国际化发展新篇章。根据弗若斯特沙利文的资料，按2023年收入计，英诺赛科在全球所有氮化镓功率半导体公司中排名第一。研发与IDM模式双轮驱动 持续巩固领先优势作为最新一代半导体材料之一，氮化镓技术及其工艺复杂，具备较高的进入壁垒。英诺赛科凭藉在氮化镓核心技术和关键工艺上的突破，在行业内建立了稳固的先发优势。公司是全球首家实现量产8英吋硅基氮化镓晶圆的公司，亦是唯一具备产业规模提供全电压谱系的硅基氮化镓半导体产品的公司。依托成熟的技术以及全面的产品组合，英诺赛科持续扩大其产品应用领域。目前，公司的产品已广泛应用于消费电子产品、可再生能源及工业应用、汽车电子及数据中心等领域。同时，公司还通过采取IDM模式的经营模式，持续巩固其领先优势。通过将设计、制造、封装及测试集于一体，英诺赛科实现对产品质量的有效把控，满足客户的大宗交付需求。此外，英诺赛科通过内部协同设计、制造等环节，实现技术上的闭环，让公司能够快速迭代其设计和工艺技术，优化产品性能和生产效率，并实现具成本效益的扩张。截至2024年6月30日，公司产能达到每月12,500片晶圆，与6英吋硅基氮化镓晶圆相比，英诺赛科每晶圆的晶粒产出数提升80%，单颗芯片成本降低30%。行业景气度高企前景可期 获众多资本加持从行业前景看，随着全球对高效能功率半导体产品需求的增加，氮化镓半导体产品近年来在不同领域被广泛应用，并展现出巨大的增长潜力。根据弗若斯特沙利文的资料，2023年至2028年，全球氮化镓功率半导体市场规模将由人民币18亿元，增至人民币501亿元，占全球功率半导体市场的份额也将由0.5%提升至10.1%。可以说，氮化镓功率半导体市场正处于爆发的前夕。英诺赛科拥有全球最大的氮化镓功率半导体生产基地，已经为抓住行业的发展机遇做好准备。在领先技术优势和经营模式的支持下，公司未来业绩潜力有望持续释放。值得一提的是，英诺赛科的发展潜力也获得了产业资本、政府机构以及国内外知名投资机构的看好。据了解，公司股东包括招银国际、韩企SK集团、Arm、宁德时代等知名投资方。本次IPO，英诺赛科还吸引了意法半导体、江苏国企混改基金、东方创联、苏州高端装备4名基石投资者合计认购1亿美元发售股份。其中，意法半导体为全球知名半导体企业，在半导体领域拥有深厚技术底蕴以及市场渠道，可与公司形成协同效应，助力公司业务发展。回到资本市场的角度，中长期看，氮化镓功率半导体市场将快速增长，行业景气度有望持续升温。英诺赛科作为该领域的的领军企业，公司竞争优势突出。随着其藉助上市进一步扩大产能、丰富产品组合、夯实技术壁垒，预计将在未来的行业发展浪潮中获取更多的市场份额，不断为高质量发展蓄力赋能。 Copyright 2025 亚太商讯 via SeaPRwire.com.
港股市场迎GaN芯片独角兽 英诺赛科掀起新一轮投资盛宴
香港, 2024年12月31日 - (亚太商讯 via SeaPRwire.com) - 在经历近三个季度的放缓后，2024年下半年以来港股IPO重返活跃，投资者信心日益增强，内地企业来港上市步伐加快。经统计，截至12月30日，全年共有70家新股登陆港交所，内地企业62家占比88%，其余9家来自本港、新加坡及美国。30日，在氮化镓（GaN）功率半导体领域独占鳌头的明星企业英诺赛科（2577.HK）登陆港交所主板，为港股市场带来又一枚稀缺优质标的。英诺赛科是全球首家实现量产8英吋硅基氮化镓晶圆的公司，亦是唯一具备产业规模提供全电压谱系的硅基氮化镓半导体产品的公司，IPO集资净额达13.02亿港元（绿鞋前）。管理团队屡创佳绩 备受机构投资者青睐英诺赛科于2017年成立，是一家致力于第三代半导体硅基氮化镓外延及器件研发与制造的高新技术企业，采用IDM全产业链模式，建立了全球首条产能最大的8英寸GaN-on-Si晶圆量产线。根据弗若斯特沙利文的资料，按收入计，公司于2023年在全球所有氮化镓功率半导体公司中排名第一。以创始人兼董事长Weiwei Luo博士和首席执行官吴金刚博士为首的管理团队，在先进材料和半导体技术领域拥有丰富的经验，带领英诺赛科在业内率先推出了氮化镓功率半导体产品，并以先进的IDM模式大获商业成功。同时，公司的研发团队不断创新，截至2024年12月10日在全球拥有406项专利及387项专利申请的广泛组合，涵盖芯片设计、器件结构、晶圆制造、封装及可靠性测试等关键领域，创造了卓越的价值。自2018年4月至2024年4月，英诺赛科成功完成A轮至E轮共五轮融资，累计融资总额达人民币62.34亿元。公司首次公开发售前投资者阵容十分庞大，引入了招银成长、吴江产投、SK China、华业天成、钛信、武汉光谷芯、珠海港湾、中天汇富等近五十家知名机构作为战略股东，为其快速发展提供雄厚的资金及资源支持。除了星光熠熠的Pre-IPO投资者外，是次IPO，英诺赛科还引入STHK、江苏国企混改基金、苏州高端装备及东方创联作为基石投资者。四名基石投资者拟认购总金额为1.00亿美元的全球发售股份，认购比例超过一半，足见全球半导体巨头、国资长线基金与专业投资机构对公司业务前景和投资价值的高度认可。把握机遇形成规模经济 高成长促估值提升自成立以来，英诺赛科持续专注于建立量产能力及投资核心技术的研发，为在蓬勃发展的氮化镓功率半导体产业中把握机遇打下基础。公司于2022年4月开始批量生产，随着产能扩大、产品供应提升以及核心技术的成熟，开始逐渐受惠于规模经济，收入获得大幅增长，市场地位亦不断提高。于2021年、2022年及2023年，英诺赛科分别录得收入约人民币6,821.5万元、1.36亿元及5.93亿元，复合年增长率为194.8%。于2024年上半年，收入由2023年同期的人民币3.08亿元，进一步增长25.2%至人民币3.86亿元，成长势头维持强劲。在半导体产业，采用IDM模式的公司通常会经历一个高投入的产业周期，即在产能增加的同时，会产生大额前期资本支出及研发开支，是以英诺赛科录得暂时的净亏损，这也是其发展过程中的必经阶段。而随着持续收入增长、规模经济增长及提升经营效率，预期在不久的将来，公司有望改善财务表现及实现盈利。当前，氮化镓功率半导体行业已逐步进入持续向上爬坡的繁荣期，产业爆发无疑将催生新的投资热土。 Copyright 2025 亚太商讯 via SeaPRwire.com.
国泰君安国际标普全球企业可持续发展评估再获提升
香港, 2024年12月31日 - (亚太商讯 via SeaPRwire.com) - 国际知名评级机构标普全球（S&P Global）近期发布了国泰君安国际控股有限公司（"国泰君安国际"或"公司"，股份代号：1788.HK）最新企业可持续发展评估（Corporate Sustainability Assessment，简称CSA）报告。报告显示，国泰君安国际CSA评分相较于上一次评估实现了7分的稳步提升，在行业中表现卓越。据报告，国泰君安国际在ESG三大维度（管治与经济维度，社会维度及环境维度）中均取得优异成绩，本次得分提升是由于公司在气候战略、人力资本管理和商业道德这三个关键领域领先于行业平均水平。其中，标普全球特别肯定了公司在商业道德实践方面的出色表现，并指出公司在必要披露和自愿披露方面的有效信息量及内容在金融服务行业中处于较高水平，这表明公司在ESG信息披露透明度方面做出了积极努力。国泰君安国际一直以来高度重视ESG议题，将其融入日常运营和管理之中。2024年，公司MSCI ESG获提升至"A"级，国内知名评级机构万得Wind ESG和商道融绿ESG均授予公司行业领先的"A"评级。通过不断优化提升，国泰君安国际在ESG领域的表现获得业内广泛认可，这不仅是对公司努力的肯定，也将进一步推动公司在ESG方面的发展。随着ESG在投资者决策中的地位不断提升，国泰君安国际出色的ESG实力无疑将为公司未来发展带来更多机遇。 Copyright 2024 亚太商讯 via SeaPRwire.com.
汇舸环保宣布于香港交易所主板上市计划
香港, 2024年12月31日 - (亚太商讯 via SeaPRwire.com) - 中国船舶环保设备及系统提供商 - 上海汇舸环保科技集团股份有限公司（「汇舸环保」或「集团」，股份代号：2613），今天宣布于香港联合交易所有限公司（「香港交易所」）主板上市计划。汇舸环保将全球发售10,000,000股H股，其中1,000,000股H股将作香港发售（可予重新分配），占初步发售股份总数10%；9,000,000股H股将于国际发售（可予重新分配），占初步发售股份总数90%，发售价介乎31.8港元至39.8港元。汇舸环保将于2024年12月31日（星期二）早上9时正，开始于香港公开发售，并于2025年1月6日（星期一）中午12时截止。集团的股份预计将于2025年1月9日（星期四）于香港联交所主板开始买卖，股份将按每手买卖单位100股买卖，股份代号为2613。中信证券（香港）有限公司及中国银河国际证券（香港）有限公司为联席保荐人、整体协调人、联席全球协调人、联席账簿管理人及联席牵头经办人。法国巴黎证券（亚洲）有限公司为整体协调人、联席全球协调人、联席账簿管理人及联席牵头经办人。汇舸环保是一家中国船舶环保设备及系统提供商，服务世界各地的航运公司及船东客户。根据弗若斯特沙利文的资料，于二零二三年十二月三十一日，按船舶废气净化系统的二零二三年已完成订单总数及累计手头订单量计，集团在中国船舶废气净化系统提供商中排名第三，在全球所有船舶废气净化系统提供商中排名第四。集团于二零一七年开展业务，推出首款产品船舶废气净化系统。现已开发及商业化销售多种船舶环保设备及系统。具体而言，集团的设备及系统旨在帮助客户（例如船东）减少硫化物及GHG 排放。此外，集团通过提供内部设计以及供应设备及系统来提高船上生活条件及加强海事作业，旨在帮助客户改善其船员的生活质素。受惠于ESG监管框架及海洋环境保护相关倡议所带动日益壮大的全球市场作为船舶环境保护设备及系统提供商，汇舸环保受惠于日趋严格的ESG 监管框架及海洋环境保护相关倡议所带动的日益壮大的全球市场。汇舸环保的设备及系统助力集团的客户追求更高效及可持续的商业运营。对集团设备及系统的需求亦受到各种ESG 相关要求的带动。例如，国际海事组织将燃料油的硫上限设定为0.5%，自二零二零年起生效，并推出EEXI 及CII 等措施，自二零二三年起生效。于二零二三年七月七日，国际海事组织修订了其GHG 减排战略，其目标是到二零五零年实现净零排放的中长期里程碑。此外，欧洲联盟从二零二四年开始引入欧盟航运排放交易系统，以及即将出台的二零二五年FuleEU 海事法规。不断发展的ESG监管框架为集团的设备及系统的销售增长做出了贡献，并将继续做出贡献。研发及创新能力，捕获快速变化的市场需求集团的研发及创新能力使其能够快速回应市场需求，开发新设备及系统，帮助船东和造船商应对不断演进的环保要求以及彼等的独特需求。例如，集团的产品船舶废气净化系统已经历四代升级，每一代在脱硫效率方面均有所提升。集团船舶废气净化系统的核心部件脱硫塔具有轻量化设计特点，可降低船舶的功耗。为缩短安装时间，节省船东船舶运作中断的时间和成本，集团已对产品进行模组化。汇舸环保位于上海及里斯本的研发团队还利用各自的优势合作建立不同研发阶段的设备及系统及交换研发成就。两个研发团队各自均可独立展开研发工作，对集团的创新战略至关重要。强大的全球服务网络，服务多元优质的客户群汇舸环保位于上海的服务中心及中国附属公司为国内及全球市场提供服务。集团位于新加坡的服务中心为东南亚市场提供服务。集团通过服务承包商提供全球服务，包括亚洲、欧洲、美洲及中东。汇舸环保的服务中心负责在集团的全球服务网络提供客户服务及技术指导，且其还进行营销活动。通过全球服务网络，集团为客户提供从售前技术咨询到售后维护的服务，已培育一个全球服务网络。汇舸环保致力保持快速响应的沟通渠道，确保全天候确认并解决客户反馈的问题。集团的客户群现在遍布多个国家及地区，包括亚洲、欧洲、美洲及中东，展示了汇舸环保的全球影响力和客户对集团设备及系统的信任。全方位的定制型船舶环境保护设备及系统集团是拥有不仅涵盖船舶脱硫系统、船舶节能装置及船舶清洁能源供应系统，同时还提供涵盖社会层面的海事服务（包括船舶内装，以改善船员的工作及生活环境）的成套设备及系统的少数从业者之一。凭借全面的产品组合，集团能够按照客户的独特需求为彼等提供定制的设备及系统组合。集团定制化方法对客户有利，因为其使集团能够客制化设备及系统，从而满足不同船舶的不同规格和技术要求。每套设备及系统均可进行定制，以符合个别的船舶类型、客户需求、航线及船舶登记，集团定制从理解客户需求开始，到进行现场3D扫描建模，形成技术建议及图纸，其后提交至船级社及客户供审查和认证，最后进行采购、制造、安装及调试。强大的供应链管理能力及严格的质量控制汇舸环保具备强大的供应链管理能力，该能力垂直整合集团设备及系统的所有关键组成部分。这进而亦确保了质量的控制。集团向国内外知名供应商采购零部件及原材料，包括海水泵，水质分析仪，烟气分析仪，以及氮气系统。汇舸环保的供应链能力使集团能够对成本、质量及进度保持控制权，确保可靠及具成本效益的设备及系统开发及业务运营。集团已建立产品质量控制体系且集团的生产设施已从包括法国船级社及劳氏船级社在内的主要船级社获得对船舶废气净化系统及相关产品的工厂认证。集团的其他产品已获得包括美国船级社、劳氏船级社、挪威船级社、法国船级社、日本海事学会及中国船级社在内的主要船级社的认证。汇舸环保采用「以销定产」模式，使集团的生产计划与销售订单量保持一致。此举最大限度地减少了生产过剩和库存过剩的风险。上海汇舸环保科技集团股份有限公司CONTIOCEAN ENVIRONMENT TECH GROUP CO., LTD.资料摘要全球发售详情：全球发售之股份数目:10,000,000股H股香港发售股份数目:1,000,000股H股(可予重新分配)国际发售股份数目:9,000,000股H股(可予重新分配)最高发售价:每股H股39.8港元，另加1%的经纪佣金、0.0027%证监会交易征费、0.00015%会财局交易征费及0.00565%联交所交易费（须于申请时以港元缴足，多缴股款视乎最终定价可予退还）每手买卖单位:100 股H股香港公开发售开始:2024年12月31日(星期二) 上午9时香港公开发售结束公布股份配售和发售结果::2025年1月6日(星期一) 中午12时2025年1月8日(星期三)预计上市日期:2025年1月9日(星期四)股份代号:2613所得款项用途：经扣除就全球发售应付的包销佣金及其他估计开支后，按发售价为每股H股35.8港元（指示性发售价范围的中位数）计算，公司估计将自全球发售收取所得款项净额约312.0百万港元，并计划作下列用途：- 约50.0%（或156.0百万港元）将用于研发。- 约15.0%（或46.8百万港元）将用于潜在并购。- 约15.0%（或46.8百万港元）将用于投资在中国内地或东南亚设立生产设施。此外，亦会就生产设施采购制造及仓储物流设备，并购置信息技术软件和硬件。- 约10.0%或31.2百万港元将用于在国际上设立四间服务中心，包括亚洲、欧洲及中东。公司亦会升级服务中心。- 约10.0%（或31.2百万港元）将用作营运资金及一般企业用途。此新闻稿由博达浩华国际财经传讯集团代表上海汇舸环保科技集团股份有限公司发布。如有垂询，请联络︰博达浩华国际财经传讯集团冯嘉莉+852 3150 6763kelly.fung@h-advisors.global杨冬梅+86 150 2184 0493may.yang@h-advisors.global薛颖心+852 3150 6782bonnie.xue@h-advisors.global Copyright 2024 亚太商讯 via SeaPRwire.com.
中国营养品行业品牌商纽曼思公布于香港主板上市计划
香港, 2024年12月30日 - (亚太商讯 via SeaPRwire.com) - 专营藻油DHA、益生菌、维生素、多维营养素及藻钙产品的中国领先母婴营养制成品营销、销售及分销商纽曼思健康食品控股有限公司（"纽曼思"或"集团"），今日公布在香港联合交易所有限公司（"香港联交所"）主板上市计划的详情。集团拟发售合共250,000,000股股份，其中225,000,000股股份作国际发售（可予重新分配），25,000,000股股份作香港发售（可予重新分配）。指示性发售价范围介乎每股发售股份0.80港元至1.09港元。假设发售价为每股发售股份0.95港元（即指示性发售价范围的中位数）及超额配股权未获行使，经扣除就全球发售应付的包销费及相关上市开支后后，预计全球发售所得款项净额约为156.3百万港元。香港公开发售将于2024年12月30日（星期一）开始，并于2025年1月7日（星期二）正午结束。股份预期将于2025年1月10日（星期五）于香港联交所主板挂牌买卖，股份代号为2530，每手买卖单位为8,000股股份。财通国际融资有限公司的独家保荐人及独家整体协调人。财通国际证券有限公司及富华建业证券有限公司为联席全球协调人、联席账簿管理人及联席牵头经办人。中国光大证券（香港）有限公司、First Fidelity Capital (International) Limited、富途证券国际（香港）有限公司、辉立证券（香港）有限公司、东吴证券国际经纪有限公司及众宸证券有限公司为联席账簿管理人及联席牵头经办人。投资亮点扎根母婴营养品行业多年，拥稳健的市场定位及高度品牌认可纽曼思早于2007年进军中国母婴营养品市场，为中国母婴营养品行业藻油DHA分部的专属品牌拥有人。集团以专属品牌"纽曼思"及"纽曼斯"（Nemans）营销营养品，满足孕妇及产后妇女、婴儿以至儿童不同阶段的营养需求。集团凭借在行业的悠久历史及良好声誉、产品质量优良加上完善且多元化的销售及分销网络，使集团从竞争对手中脱颖而出，并持续保持竞争优势，从而把握市场上不断涌现的机遇。纽曼思之业务稳步上升，收益由2021财政年度的约人民币337.6百万元增加至2023财政年度的约人民币426.5百万元；毛利率于2021至2023财政年度、以及2023及2024年6个月，维持稳定于70%以上。经调整纯利[1]由2021财政年度的约人民币130.4百万元增加至2023财政年度的约人民币172.3百万元，升幅达32%。根据弗若斯特沙利文咨询报告，集团在2023财政年度于中国藻油DHA市场的零售销售值，无论是与中国市场国际及国内藻油DHA品牌相比，还是仅与国内藻油DHA品牌比较，均位居首位。凭借藻油DHA产品的成功，集团持续推广其专属品牌下的其他营养品（如益生菌、维生素、多维营养素及藻钙产品），以满足消费者的不同需求和消费偏好。多年来，集团荣获包括2021天猫双11全球狂欢节的"增长引擎奖"、"2022年度天猫婴童食品行业奖 - 年度超级单品奖 - 年度宝宝营养品"及"2023财年天猫国际品类冠军营"在内的各种奖项，彰显其营养品深受市场认可。多元销售渠道，扩大市场渗透纽曼思在中国拥有多元化且覆盖线上及线下渠道的销售及分销网络。集团的线上销售渠道包括在中国流行的网购平台，而鉴于近年来电子商务日益普及加上消费者对网上资讯的依赖，集团亦会透过线上销售渠道提供资讯及宣传其营养品与品牌。于2021财政年度、2022财政年度、2023财政年度及2024年6个月，线上销售渠道的收益占相应年度╱期间的收益分别64.1%、66.3%、73.0%及80.7%。于往绩期间，集团有绝大部分的收益来自网购平台，包括淘宝、抖音及京东。线下销售渠道方面，于2024年6月30日，集团委聘了17名地区分销商于中国各地销售及分销产品。集团的产品借助该等地区分销商的下游销售渠道，如药房、母婴产品店、产后护理中心、零售店及其次级分销商，渗透入中国各地的市场。集团亦定期对各分销商进行管理、监察并培训，确保他们熟知集团的营养品。该等线下销售渠道布局，令集团的产品得以覆盖中国多地，并加速进入中国各主要城市的步伐。集团相信，其在中国的多元化销售及分销网络赋予集团坚实的基础，以利于进一步扩大产品销售，并提高产品及品牌的市场认可度。同时，该等多元化的销售及分销网络亦有助集团降低在任何当地市场的集中风险。策略性地选择主要原材料海外供应商，提升市场信心纽曼思相信，维持营养品所用原材料的质量及安全是成功的关键。因此，集团透过策略性地选择营养品的主要原材料海外供应商，维护及保持产品质量。具体而言，集团严格要求藻油DHA成品供应商使用全球藻油DHA市场的领导者帝斯曼集团[2]供应的主要原材料，及要求所有益生菌产品的供应商使用益生菌原材料供应商[3]供应的原材料。根据弗若斯特沙利文咨询报告，使用国际一流原材料的产品备受中国母婴营养品行业的消费者欢迎。因此，集团这一策略有助保证其产品质量、提升消费者信心，从而维护及提高集团的声誉。集团对产品品质的坚持亦备受行业肯定。集团荣获由宝宝树（中国孕产妇及婴儿社区平台）颁发的"Babytree宝宝树金树奖 - 2020年度优质国民品牌奖"，由CBME孕婴童展颁发的"CBME 2020感恩同行共生未来 - 荣耀品牌伙伴奖"及由育儿网（一家中国育儿网站）颁发的"2021年度育儿网橙品清单妈妈口碑之选 - 宝宝用品年度人气营养品"。集团亦于2019年至2021年连续三年获得由母婴行业观察及樱桃大赏评委会颁发的"樱桃大赏 - 年度婴幼儿营养品品牌最佳表现力大奖"及于2022年获得"第八届樱桃大赏 - 年度婴幼儿营养品品牌杰出表现力大奖"；并于2023年，再次荣获"天猫国际母婴行业紫曜雷霆奖"。管理团队经验丰富，确保业务可持续发展纽曼思由一支经验丰富及尽忠职守的管理团队带领，团队具备有关中国营养品市场的丰富经验及渊博知识。集团的主席、行政总裁及执行董事王平先生于企业营运及管理方面拥有超过20年经验，自集团成立以来一直管理本集团。而负责集团整体营运及管理的安勇先生，曾任澳美澳乳业总经理，拥有超过17年的食品行业。同时，集团的其他高级管理层成员于营养品行业拥有多年经验或具备相关的管理和财务专长，令集团得以制定及实施适当的业务策略，快速应对中国营养品市场瞬息万变的市场环境及需求，有助集团实现可持续增长。业务策略纽曼思的业务目标是实现可持续增长、提高市场份额及巩固集团在中国营养品市场的市场地位。为进一步实现该等目标，集团计划采取以下策略：透过多种方法增加营销投入，提升集团品牌知名度纽曼思相信，成功的品牌建设是业务发展的关键。集团已经将"纽曼思"及"纽曼斯"（英文名称为"Nemans"）发展为在中国获高度认可的品牌。自2007年首次对出DHA产品以来，集团的营销、销售及分销主要集中于中国的一线、新一线及二线城市，但广东省、江苏省、山东省、浙江省及安徽省的若干三、四线城市（如汕头、江门、揭阳、湛江、肇庆、潮州、清远等）（"选定城市"）的营养品行业亦存在巨大潜力和机遇。根据弗若斯特沙利文咨询报告，选定城市的营养品市场总规模2018至2023年复合年增长率约为28.6%，预期至2028年复合年增长率将达19.9%；其年度人均可支配收入约为人民币25,000元至人民币68,000元，与该等省份的一、二线城市有或多或少的重迭区间；由于业内领先品牌历来集中在中国的一线、新一线及二线城市进行营销及销售，选定城市的市场竞争亦较小。有见及此，为进一步推广产品、提升品牌知名度及形象，并加强尤其是对现有销售及分销网络尚未覆盖或覆盖不足的较低发展地区的渗透力，集团拟透过不同的方式加强市场营销工作，进一步扩大销售及分销网络，提高线上及线下渠道的销售额。对于线上渠道，集团将在社交媒体平台及网购平台进行网上营销以及推广其品牌及产品。而针对线下渠道，集团将扩大线下销售网络、举办及参与会议、大型贸易展览会及业界活动。集团已计划于未来三年各年底前举办约15至20场会议。在香港推广集团的产品，并将销售网络扩展到当地根据弗若斯特沙利文咨询报告，鉴于在中国母婴营养品行业，使用进口原材料的产品颇受客户青睐，国内品牌在香港开设办事处和商店，应可进一步加强其进口原材料和海外加工的产品在客户心中的形象及印象，而在香港销售的营养品亦被中国消费者认为更值得信赖和可靠。因此，集团计划透过在香港推广其产品，并将销售网络延伸至当地，进一步加强其品牌形象。为此，集团拟在香港中环一个购物中心设立一家零售店；加之其藻油DHA及益生菌产品使用国际供应商提供的主要原材料，集团相信，有关策略可进一步加强集团品牌的国际元素。同时，集团计划聘请设于香港的独立营销代理，在香港为集团的产品开展一系列的促销活动。有关营销及推广服务将包括：电视广告、户外平面广告、开幕活动管理、赞助管理、数字平台策略性推广，及在婴童展和其他巡回展览中进行推广。集团亦拟于香港设立一个办事处及仓库，以支持集团当地零售店运作及产品分销。所得款项用途项目约向着名且受欢迎的KOL购买营销及推广服务34.5%购买电商公司的品牌营销及推广产品22.0%参与会议及大型贸易展览会及业界活动7.0%在香港中环一座购物中心设立零售店12.6%聘请香港的独立营销代理18.0%在香港设立办事处及仓库5.9%关于纽曼思健康食品控股有限公司纽曼思健康食品控股有限公司是一家专注于高品质藻油DHA、益生菌、维生素、多维营养素及藻钙产品的中国领先营养制成品营销、销售及分销商。作为中国母婴营养品行业藻油DHA分部的专利品牌拥有人，集团旗下两大核心品牌"纽曼思"及"纽曼斯"（Nemans），透过多元化的销售及分销网络，为中国消费者提供优质的健康及营养解决方案。根据弗若斯特沙利文咨询报告，集团在2023财政年度于中国藻油DHA市场的零售销售值，无论是与中国市场国际及国内藻油DHA品牌相比，还是仅与国内藻油DHA品牌比较，均位居首位。此外，在使用海外供应商供应的藻油DHA原材料的中国前五大母婴藻油DHA国内品牌中（总计市占率达62.3%），集团的零售销售值高居榜首。如欲了解更多，请访问集团官方网站：https://www.numans.cc/[1] 经调整纯利（非香港财务报告准则计量）的定义为加回上市开支的经调整年╱期内纯利。[2] 根据弗若斯特沙利文咨询报告，帝斯曼集团被视为中国藻油DHA市场的领导者，按产量及价值计算，于2023年制造中国藻油DHA市场超过40%的原材料及成品。[3] 根据弗若斯特沙利文咨询报告，该供货商于2023年为中国最大益生菌原材料供货商之一，占当年中国益生菌原材料供应市场总收益约35% Copyright 2024 亚太商讯 via SeaPRwire.com.